By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax  Antibody phage display

Company News
Amgen (AMGN)'s Blincyto Successful in Phase III Leukemia Trial 2/5/2016 6:15:11 AM
Amgen (AMGN)'s Repatha Met Co-Primary Endpoints in Phase III GAUSS-3 Study 2/4/2016 2:25:20 PM
Amgen (AMGN) Releases Secret Data on Three Failed Studies to Confirm Findings in High Profile Journals 2/4/2016 6:45:35 AM
Three Biotech Stocks You Don't Have to Constantly Monitor 2/2/2016 7:15:49 AM
Amgen (AMGN)'s 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (Eps) Increased 19 Percent To $10.38 1/29/2016 7:30:24 AM
Health Canada Approves Amgen (AMGN)'s New Multiple Myeloma Treatment Kyprolis (carfilzomib) 1/28/2016 5:59:29 AM
FDA Accepts Amgen (AMGN)'s Biosimilar Biologics License Application For ABP 501 1/26/2016 5:55:34 AM
Amgen (AMGN) Announces Webcast Of 2015 Fourth Quarter And Full Year Financial Results 1/25/2016 2:51:11 PM
Investors Hope Biogen (BIIB), Amgen (AMGN) and Celgene (CELG)'s Earnings Will Pull Biotech Sector Out of Slump 1/25/2016 6:36:29 AM
Amgen (AMGN)'s Vectibix + BSC Meets Primary Endpoint in Phase III Study 1/25/2016 5:50:46 AM